Yttrium 90-labelled edotreotide is under clinical development by Progenics Pharmaceuticals and currently in Phase II for Neuroblastoma. According to GlobalData, Phase II drugs for Neuroblastoma have a 28% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how Yttrium 90-labelled edotreotide’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Yttrium 90-labelled edotreotide overview
Onalta (edotreotide Labeled Yttrium 90) is under development for the treatment of neuroblastoma, medulloblastoma and meningioma. The drug candidate is administered as intravenous and intra-arterial infusion. Onalta (yttrium-90 radiolabeled edotreotide) is a radiolabeled somatostatin analog. The compound has potential to selectively deliver yttrium-90, which is a lethal radiation to cancer cells. Onalta binds selectively to tumor cells that have somatostatin receptors type 2 and 5. The drug candidate was also under development for the treatment of small-cell lung cancer, metastatic breast cancer and neuroendocrine tumors.
Progenics Pharmaceuticals overview
Progenics Pharmaceuticals (Progenics) is a biopharmaceutical company.
For a complete picture of Yttrium 90-labelled edotreotide’s drug-specific PTSR and LoA scores, buy the report here.